 |
English | deutsch | Impressum | ||
| Sitemap | Disclaimer |
 |
 |
 |
 |
 |
 |
 |
|
Pipeline |
MN/CA IX Antigen – A Highly Specific Tumour Target RENCAREX®* (WX-G250) targets the antigen carbonic anhydrase IX (CA IX, MN, or G250 antigen) in a highly specific manner. MN/CA IX is a cell surface antigen expressed in over 90% of all clear cell RCC, but not expressed in normal kidney tissue. The antigen is also present in bladder cancer and a variety of other solid tumours, including biliary, cervical, colon, breast, and NSCL cancer. In normal tissue the antigen is expressed at low levels and restricted to the gastric epithelium, upper intestinal tract epithelium, and the bile ducts, but is undetected in normal kidney and other tissues. |
|
 Fig.: IHC Staining Illustration of RCC and healthy kidney tissue shows the high specifity of the antibody. RENCAREX® (WX-G250) does not bind to normal kidney tissue (greyish area, lower right) but stains specifically only renal cell cancer (brownish area, upper left). |
||
Mode of Action of RENCAREX®– ADCC The WX-G250 antibody binds to the MN/CA IX antigen
expressed on the tumour cells, thereby triggering an immune reaction
called Antibody-Dependent Cellular Cytotoxicity (ADCC). Through this
mechanism,
effector cells, e.g. NK (natural killer) cells, of the immune system
are activated
to kill the tumour cells.  Fig.: ADCC mechanism of action. The variable region of the WX-G250 antibody binds to MN/CA IX expressed on the tumour cells. The constant region of WX-G250 binds to the Fc receptor of natural killer cells (NK cells). NK cells act as effector cells, which destroy the tumour cells.
|
 |
|
| * temporary name while under development | ||
| © 2006 WILEX AG |
Overview
Therapeutic Target